Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer

Journal of Surgical Oncology

Volumn 97, Issue 1, 2008, Pages 51-56

  Lim, Sung Chul ^a   Lee, Tae Bum ^a   Choi, Cheol Hee ^a   Ryu, So Yeon ^a   Min, Young Don ^a   Kim, Kyung Jong ^a  

^a Chosun University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; Cyclooxygenase 2; p53; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; CANCER PATIENT; CANCER SURVIVAL; CELL NUCLEUS; COLORECTAL CANCER; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38149029210     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20907     Document Type: Conference Paper

References (32)

1. Boyle P, Zaridze DG, Smans M: Descriptive epidemiology of colorectal cancer. Int J Cancer 1985;36:9-18.
2. Annual Report of the Korea Central Cancer Registry 2002, Ministry of Health and Welfare Republic of Korea, 2002.
3. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
4. Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916.
5. Fosslien E: Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
6. Subbaramaiah K, Dannenberg AJ: Cyclooxygenase2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
7. Subbaramaiah K, Altorki N, Chung WJ, et al.: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911-10915.
8. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-140.
9. Manne U, Weiss HL, Myers RB, et al.: Nuclear accumulation of p53 in colorectal adenocarcinoma: Prognostic importance differs with race and location of the tumor. Cancer 1998;83:2456-2467.
10. Yamauchi T, Watanabe M, Kubota T, et al.: Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98-103.
11. Soumaoro LT, Uetake H, Higuchi T, et al.: Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471.
12. Xiong B, Sun TJ, Hu WD, et al.: Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 2005;11:1105-1108.
13. Konno H, Baba M, Shoji T, et al.: Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002;19:527-534.
14. Masunaga R, Kohno H, Dhar DK, et al.: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-4068.
15. Tomozawa S, Tsuno NH, Sunami E, et al.: Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-328.
16. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-3340.
17. Tsujii M, Kawano S, Tsuji S, et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
18. Fujita T, Matsui M, Takaku K, et al.: Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-4826.
19. Sheehan KM, Sheahan K, O'Donoghue DP, et al.: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-1257.
20. Soumaoro LT, Uetake H, Takagi Y, et al.: Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006;49:392-398.
21. Fux R, Schwab M, Thon KP, et al.: Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-4760.
22. Bargonetti J, Manfredi JJ: Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
23. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991;351:453-456.
24. Harris CC, Hollstein M: Clinical implication of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-1327.
25. Wang WS, Lin JK, Chiou TJ, et al.: CA 19-9as the most significant prognostic indicatior of metastatic colorectal cancer. Hepatogastroenterology 2002;49:160-164.
26. Kressner U, Lindmark G, Gerdin B, et al.: Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 1996;16:951-957.
27. Popat S, Chen Z, Zhao D, et al.: A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006;17:1810-1817.
28. Dix BR, Robbins P, Soong R, et al.: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994;59:747-751.
29. Lan YT, Chang SC, Fen-Yau Li A, et al.: p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 2007;22:499-506.
30. Cressey R, Pimpa S, Tontrong W, et al.: Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Lett 2006;233:232-239.
31. Sakuma K, Fujimori T, Hirabayashi K, et al.: Cyclooxygenase (COX)-immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol 1999;34:189-194.
32. Liang JT, Huang KC, Jeng YM, et al.: Microvessel density, cyclooxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 2004;91:355-361.